All In Biotech

Drug Trial Radar · NCT05204368

Evaluation of the Efficacy and Safety of Intravenous Imipenem/Cilastatin/XNW4107 in Comparison With Meropenem in Hospitalized Adults With cUTI Including AP (EudraCT no. 2022-000061-40)

A Multicenter, Randomized, Double-Blind, Double-Dummy, Comparative, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous Imipenem/Cilastatin/XNW4107 in Comparison With Meropenem in Hospitalized Adults With Complicated Urinary Tract Infections, Including Acute Pyelonephritis.(EudraCT no. 2022-000061-40)

Last checked: Nov 19, 2026Latest source record: Feb 16, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 780 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

780

Planned (sponsor's estimate)

Start

Mar 30, 2023

Primary completion

Jun 2025

Study completion Dec 2025

Sponsor

Lead sponsor
Evopoint Biosciences Inc.Industry
Sponsor type
Industry
First posted
Jan 24, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is A Multicenter, Randomized, Double-Blind, Double-Dummy, Comparative, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous Imipenem/Cilastatin/Funobactam in Comparison with Meropenem in Hospitalized Adults with Complicated Urinary Tract Infections, including Acute Pyelonephritis.

Conditions

  • Complicated Urinary Tract Infection Including Acute Pyelonephritis

Interventions

  • Combination of Imipenem/Cilastatin and XNW4107Drug

    Imipenem/Cilastatin 500mg/500mg and XNW4107 250mg for injection

  • MeropenemDrug

    Meropenem 1g for injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. overall successTime frame: Day 21[±2 days]

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Maryland Medical Center

    Baltimore, Maryland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.